Kinfo
DiaMedica Therapeutics Inc. logo

DiaMedica Therapeutics Inc.

DMACNASDAQHealthcare·US · USD
$8.01
+0.02 (+0.25%)
Prices as of October 8, 2026 · market closed

Price

Key statistics

Valuation
Market cap431.94M USD
Enterprise value395.10M USD
Trailing P/E-11.43
Forward P/E-10.06
PEG ratio-2.06
Price / sales0.00
Price / book11.43
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-64.12%
Return on equity-114.61%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA-39.17M USD
Net income-37.54M USD
Diluted EPS-$0.72
Rev. growth (YoY)0.00%
Balance sheet
Total cash43.50M USD
Total debt185.00K USD
Debt / equity0.48
Current ratio6.72
Book value / share$0.71
Cash flow (TTM)
Operating cash flow-31.51M USD
Levered free cash flow-17.65M USD
Shares & price
Shares outstanding53.93M
Float25.30M
Held by institutions40.91%
Beta0.91
50-day MA$6.93
200-day MA$7.10
52-week high$10.42
52-week low$5.25
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-10-0.20-0.19+5.00%2026-05-06-0.18-0.19−5.56%2026-03-30-0.18-0.17+5.56%2026-01-231.611.87+16.15%
About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious vascular and ischemic diseases. Its current pipeline is centered on DM199, a recombinant form of human tissue kallikrein-1 being studied for acute ischemic stroke, preeclampsia, fetal growth restriction, and other conditions linked to impaired blood flow. The company also advances DM300, a recombinant human ulinastatin candidate in preclinical development for inflammatory disorders. DiaMedica Therapeutics serves the neuroscience, women’s health, renal, and inflammatory disease areas through therapies designed to address significant unmet medical needs. Headquartered in Minneapolis, Minnesota, DiaMedica Therapeutics Inc. operates as a specialized biotech platform focused on recombinant protein-based drug development.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Dietrich John Pauls MBA
Employees
35
Headquarters
Minneapolis, MN, United States

Frequently asked questions about DiaMedica Therapeutics Inc.